Three key points emerged from the document: 1) Patient advocacy groups and unions see the choice of drug as a matter between doctors and patients, and do not want employers, governments, or others interfering in drug decisions. 2) Both patient groups and unions want new drugs and devices to be publicly funded, believing they are safer and more effective, though cost is a major concern for Pharmacare plans and employers. 3) Unions and their members generally support the idea of national Pharmacare but more education is needed to help members understand and support evidence-based managed formularies being negotiated by employers.